Some of the most in-demand wellness treatments live in a regulatory gray zone, and offering them without understanding the rules can void your insurance and expose you to enforcement. Ozone therapy, exosomes, and anything labeled 'research use only' deserve special caution.
Take ozone first. The FDA's stated position is blunt: ozone is a toxic gas with no known useful medical application in general medicine. A practice offering ozone therapy is operating in a space where the federal position is explicitly unfavorable, which shapes both compliance risk and whether a carrier will stand behind a claim.
Exosomes are a rapidly growing area with serious regulatory attention. Many exosome products are not FDA-approved for the uses they are marketed for, and the agency has warned about unapproved products in the regenerative space. Products marketed for human treatment while labeled 'research use only' are a particular red flag, that label signals the product was never cleared for patient care, and using it that way can be treated as using an unapproved product.
Here is the coverage trap that ties them together. Insurance is built around approved, disclosed, defensible care. Gray-market and unapproved treatments frequently fall outside what a policy covers, and using 'research use only' materials on patients can place a treatment squarely outside coverage. A practice can face a claim on one of these services and find it entirely uncovered.
There is also a sourcing dimension. Gray-market products often come through distribution channels that cannot document proper manufacturing or handling. If a product harms a patient and you cannot show legitimate sourcing, both the liability and the coverage picture worsen sharply.
None of this means innovation is off-limits. It means these treatments demand extra diligence: understand each product's actual regulatory status, avoid anything marketed for patient use under a 'research use only' label, source only through legitimate channels, and, critically, confirm in writing whether your coverage extends to them before you offer them.
In more than 25 years in this field, gray-market treatments are where we most often see the gap between what a practice thinks it is covered for and what it is actually covered for.
Cutting-edge can be good medicine and good business. But 'research use only' on a patient is a phrase that can quietly void everything protecting you.
Offering ozone, exosomes, or other gray-market treatments? Your standard policy may not cover them at all. We specialize in coverage for advanced and regenerative practices, with over 25 years of experience. Check your eligibility and find out where you actually stand.
Check Your EligibilityWhat is the FDA's position on ozone therapy?
The FDA states that ozone is a toxic gas with no known useful medical application in general medicine. Practices offering ozone therapy operate where the federal position is explicitly unfavorable, which affects both compliance and coverage.
Are exosome treatments FDA-approved?
Many exosome products are not FDA-approved for the uses they are marketed for, and the FDA has warned about unapproved products in the regenerative space. Offering them requires understanding each product's actual regulatory status.
What does 'research use only' mean for patient treatments?
It means the product was never cleared for patient care. Using a research-use-only product on patients can be treated as using an unapproved product, and typically falls outside insurance coverage.
Will my insurance cover gray-market or unapproved treatments?
Often not. Insurance is built around approved, disclosed, defensible care. Gray-market and unapproved treatments frequently fall outside coverage. Confirm in writing whether your policy extends to these before offering them.
[[YULIA_DISCLAIMER]]
Not sure whether your advanced treatments are covered or exposed? Schedule a free consultation. We will review your service menu and show you exactly where your coverage begins and ends.
Schedule a Free Consultation